AlloVir Management

Management Kriterienprüfungen 3/4

AlloVir's CEO ist Diana Brainard , ernannt in May 2021, hat eine Amtszeit von 3.08 Jahren. Die jährliche Gesamtvergütung beträgt $6.06M , bestehend aus 10.3% Gehalt und 89.7% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.26% der Aktien des Unternehmens, im Wert von $216.96K . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 5.4 Jahre bzw. 3.9 Jahre.

Wichtige Informationen

Diana Brainard

Geschäftsführender

US$6.1m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	10.3%
Amtszeit als Geschäftsführer	3.2yrs
Eigentum des Geschäftsführers	0.3%
Durchschnittliche Amtszeit des Managements	5.5yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	4yrs

Jüngste Management Updates

Recent updates

Here's Why We're Not Too Worried About AlloVir's (NASDAQ:ALVR) Cash Burn Situation

Mar 21

AlloVir: A Comparative Study Of Its Manufacturing Process

Feb 07

We're Not Very Worried About AlloVir's (NASDAQ:ALVR) Cash Burn Rate

Nov 02

AlloVir, Inc.: Creating Solutions For Stem Cell Transplant Issues

Oct 02

AlloVir, Inc.'s (NASDAQ:ALVR) Intrinsic Value Is Potentially 24% Below Its Share Price

Aug 06

We Think AlloVir (NASDAQ:ALVR) Can Afford To Drive Business Growth

Jul 01

AlloVir EPS misses by $0.08

May 06

AlloVir (NASDAQ:ALVR) Is In A Good Position To Deliver On Growth Plans

Apr 01

This Insider Has Just Sold Shares In AlloVir, Inc. (NASDAQ:ALVR)

Feb 07

Is AlloVir, Inc.'s (NASDAQ:ALVR) Shareholder Ownership Skewed Towards Insiders?

Jan 08

FDA clears AlloVir's ALVR106 application in respiratory viruses

Dec 17

Allovir's COVID-19 therapy saw anti-viral activity in pre-clinical data

Dec 07

We Think AlloVir (NASDAQ:ALVR) Can Afford To Drive Business Growth

Dec 04

AlloVir EPS misses by $0.28

Nov 10

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Diana Brainard im Vergleich zu den Einnahmen von AlloVir verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Mar 31 2024	n/a	n/a	-US$180m
Dec 31 2023	US$6m	US$623k	-US$190m
Sep 30 2023	n/a	n/a	-US$169m
Jun 30 2023	n/a	n/a	-US$167m
Mar 31 2023	n/a	n/a	-US$166m
Dec 31 2022	US$9m	US$605k	-US$169m
Sep 30 2022	n/a	n/a	-US$189m
Jun 30 2022	n/a	n/a	-US$192m
Mar 31 2022	n/a	n/a	-US$185m
Dec 31 2021	US$15m	US$365k	-US$172m
Sep 30 2021	n/a	n/a	-US$139m
Jun 30 2021	n/a	n/a	-US$117m
Mar 31 2021	n/a	n/a	-US$91m
Dec 31 2020	US$597k	n/a	-US$70m

Vergütung im Vergleich zum Markt: DianaDie Gesamtvergütung ($USD6.06M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD678.50K).

Entschädigung vs. Einkommen: DianaDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

Diana Brainard (52 yo)

3.2yrs

Amtszeit

US$6,056,943

Vergütung

Dr. Diana M. Brainard, MD., served as an Entrepreneur Partner at MPM Asset Management, L.L.C. since 2024. She served as an Executive Partner and Entrepreneur at MPM Asset Management, L.L.C. till December 2...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
David Hallal	Executive Chairman of the Board	5.8yrs	US$347.00k	2.47% $ 2.0m
Diana Brainard	CEO & Director	3.2yrs	US$6.06m	0.26% $ 211.4k
Vikas Sinha	President	5.5yrs	US$2.94m	0.81% $ 662.9k
Edward Miller	General Counsel & Secretary	5.5yrs	US$1.89m	0.37% $ 301.9k
Brett Hagen	Chief Accounting Officer	5.5yrs	keine Daten	0.067% $ 54.6k
Ann Leen	Chief Scientific Officer	11.5yrs	keine Daten	2.03% $ 1.7m
Cintia Piccina	Chief Commercial Officer	1.1yrs	keine Daten	keine Daten

5.5yrs

Durchschnittliche Betriebszugehörigkeit

52yo

Durchschnittliches Alter

Erfahrenes Management: ALVRDas Führungsteam des Unternehmens verfügt über eine langjährige Erfahrung (5.4 ).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
David Hallal	Executive Chairman of the Board	5.8yrs	US$347.00k	2.47% $ 2.0m
Diana Brainard	CEO & Director	4yrs	US$6.06m	0.26% $ 211.4k
Vikas Sinha	President	5.5yrs	US$2.94m	0.81% $ 662.9k
John Mellors	Member of the Scientific Advisory Board	1.4yrs	keine Daten	keine Daten
Malcolm Brenner	Independent Non-Executive Director	12.5yrs	US$196.28k	0.20% $ 165.6k
Jeffrey Bornstein	Independent Non-Executive Director	4yrs	US$211.78k	0.066% $ 54.4k
Michael Boeckh	Member of Scientific Advisory Board	1.4yrs	keine Daten	keine Daten
John DiPersio	Member of Scientific Advisory Board	1.4yrs	keine Daten	keine Daten
Anil Chandraker	Member of Scientific Advisory Board	1.4yrs	keine Daten	keine Daten
Morana Jovan-Embiricos	Independent Non-Executive Director	5.2yrs	US$209.28k	8.72% $ 7.2m
Shawn Tomasello	Independent Director	2.3yrs	US$200.73k	0.031% $ 25.3k
Juan Vera	Non-Executive Director	10.5yrs	US$187.00k	2.09% $ 1.7m

4.0yrs

Durchschnittliche Betriebszugehörigkeit

58yo

Durchschnittliches Alter

Erfahrener Vorstand: ALVRDie Vorstandsmitglieder gelten als erfahren (3.9 Jahre durchschnittliche Amtszeit).

AlloVir Management

Management Kriterienprüfungen 3/4

Wichtige Informationen

Jüngste Management Updates

AlloVir, Inc., Annual General Meeting, Jun 06, 2024

Allovir Announces Appointment of Cintia Piccina as Chief Commercial Officer

High number of new directors

CEO & Director notifies of intention to sell stock

Consultant notifies of intention to sell stock

Allovir, Inc. Announces the Resignation of Jeroen Van Beek as Executive Vice President and Chief Commercial Officer, Effective November 23, 2022

Recent updates

New major risk - Financial position

AlloVir, Inc., Annual General Meeting, Jun 06, 2024

New major risk - Revenue and earnings growth

Levi & Korsinsky, LLP Notifies Investors in Allovir, Inc. of a Class Action Securities Lawsuit

We Think AlloVir (NASDAQ:ALVR) Needs To Drive Business Growth Carefully

Robbins LLP Announces Class Action File Against AlloVir, Inc

Pomerantz Law Firm Announces the Filing of a Class Action Against AlloVir, Inc. and Certain Officers

Pomerantz Law Firm Announces the Filing of a Class Action Against AlloVir, Inc. and Certain Officers

Price target decreased by 71% to US$5.63

AlloVir, Inc. Provides Updates on Phase 3 Clinical Development Program for Posoleucel, an Allogeneic Virus-Specific T Cell Therapy

Here's Why We're Watching AlloVir's (NASDAQ:ALVR) Cash Burn Situation

Here's Why We're Watching AlloVir's (NASDAQ:ALVR) Cash Burn Situation

New major risk - Share price stability

AlloVir, Inc. Presents Positive Final Results from A Phase 2 Randomized, Placebo-Controlled Trial Evaluating Posoleucel Treatment of Bk Infection in Kidney Transplant Recipients At the American Transplant Congress

Allovir Announces Appointment of Cintia Piccina as Chief Commercial Officer

Is AlloVir (NASDAQ:ALVR) In A Good Position To Deliver On Growth Plans?

High number of new directors

Price target decreased by 7.6% to US$21.25

AlloVir Announces Positive Final Results from Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Posoleucel in Kidney Transplant Recipients with BK Viremia

Price target decreased by 13% to US$23.00

CEO & Director notifies of intention to sell stock

AlloVir, Inc. Announces Plans to Complete Enrollment in Three Phase 3 Posoleucel Studies in 2023

AlloVir, Inc. Announces Positive Final Results in Phase 2 Posoleucel Multi-Virus Prevention Study

Consultant notifies of intention to sell stock

Allovir, Inc. Announces the Resignation of Jeroen Van Beek as Executive Vice President and Chief Commercial Officer, Effective November 23, 2022

General Counsel & Secretary notifies of intention to sell stock

Is AlloVir (NASDAQ:ALVR) In A Good Position To Deliver On Growth Plans?

AlloVir, Inc. Announces That Final Data from the Phase 2 Study of Posoleuce

Chief Accounting Officer recently sold US$99k worth of stock

Executive Chairman of the Board notifies of intention to sell stock

Chief Accounting Officer recently sold US$99k worth of stock

Executive Chairman of the Board recently sold US$2.9m worth of stock

Chief Commercial Officer recently sold US$129k worth of stock

Price target decreased to US$27.50

AlloVir GAAP EPS of $0.69 beats by $1.42

AlloVir stock surges on $126.6M securities offering

Is AlloVir (NASDAQ:ALVR) In A Good Position To Invest In Growth?

AlloVir, Inc.(NasdaqGS:ALVR) dropped from Russell 2000 Growth Index

AlloVir, Inc. Reports Blinded, Preliminary, Phase 2 Data Supporting the Ongoing Study of Posoleucel, a Multi-Virus-Specific T Cell Therapy, for the Treatment of BK Viremia in Kidney Transplant Recipients

Chief Commercial Officer recently sold US$67k worth of stock

Price target decreased to US$32.00

FDA Grants Regenerative Medicine Advanced Therapy to Allovir's Posoleucel for Prevention of Multiple Life-Threatening Infections from Six Viruses in Allogeneic Hematopoietic Cell Transplant Patients

AlloVir, Inc., Annual General Meeting, May 17, 2022

AlloVir Announces Appointment of Shawn Tomasello to its Board of Directors

Here's Why We're Not Too Worried About AlloVir's (NASDAQ:ALVR) Cash Burn Situation

Chief Commercial Officer recently sold US$128k worth of stock

AlloVir: A Comparative Study Of Its Manufacturing Process

Price target decreased to US$38.75

Insider notifies of intention to sell stock

President recently sold US$56k worth of stock

AlloVir, Inc. Announces U.S. Food and Drug Administration Grant Lead Multi-Virus Specific T Cell (VST) Therapy, Posoleucel (Viralym-M, ALVR105), Regenerative Medicine Advanced Therapy (RMAT) Designation for the Treatment of Adenovirus (AdV) Infection

Price target decreased to US$42.75

AlloVir Announces Positive Preliminary Data from the Ongoing Phase 2 Posoleucel Multi-Virus Prevention Study at the 63rd American Society of Hematology Annual Meeting

Chief Commercial Officer recently sold US$321k worth of stock

Chief Scientific Officer notifies of intention to sell stock

We're Not Very Worried About AlloVir's (NASDAQ:ALVR) Cash Burn Rate

High number of new directors

Independent Non-Executive Director notifies of intention to sell stock

Insider recently sold US$447k worth of stock

AlloVir, Inc.: Creating Solutions For Stem Cell Transplant Issues

Insider notifies of intention to sell stock

AlloVir, Inc.'s (NASDAQ:ALVR) Intrinsic Value Is Potentially 24% Below Its Share Price

We Think AlloVir (NASDAQ:ALVR) Can Afford To Drive Business Growth

AlloVir, Inc.(NasdaqGS:ALVR) dropped from Russell 3000E Value Index

Chief Scientific Officer recently sold US$3.4m worth of stock

AlloVir EPS misses by $0.08

AlloVir (NASDAQ:ALVR) Is In A Good Position To Deliver On Growth Plans

Insider notifies of intention to sell stock

Independent Non-Executive Director notifies of intention to sell stock